Alvotech (ALVO) Consolidated Net Income (2021 - 2026)
Alvotech (ALVO) posted Consolidated Net Income of $123000.0 for Q1 2026, down 99.96% on a QoQ basis from $299.9 million in Q4 2025, and down 99.9% year-over-year from $126.2 million in Q1 2025.
Alvotech (ALVO) Consolidated Net Income (2021 - 2026) Analysis & Trends
Alvotech's Consolidated Net Income history runs 6 years deep, the most recent figure standing at $123000.0 for Q1 2026.
- Quarterly Consolidated Net Income fell 99.9% year-over-year to $123000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $50.1 million (up 119.86% YoY) and the FY2025 annual result came in at $27.9 million, up 111.31% from the prior year.
- Consolidated Net Income was $123000.0 for Q1 2026 at Alvotech, down from $299.9 million in the prior quarter.
- Across five years, Consolidated Net Income topped out at $299.9 million in Q4 2025 and bottomed at -$651.1 million in Q4 2023.
- A 5-year average of -$77.7 million and a median of -$246152.0 in 2023 frame the typical range for Consolidated Net Income.
- Annual changes were most pronounced in 2022 — Consolidated Net Income slumped 362.17% — and 2025, when it surged 59308.58%.
- Alvotech's Consolidated Net Income stood at -$540.7 million in 2022, then retreated by 20.43% to -$651.1 million in 2023, then jumped by 65.69% to -$223.4 million in 2024, then jumped by 234.25% to $299.9 million in 2025, then sank by 99.96% to $123000.0 in 2026.
- Business Quant data shows ALVO's Consolidated Net Income at $123000.0 in Q1 2026, $299.9 million in Q4 2025, and -$307.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.58 Bn | 86.72 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.90 Bn | 32.16 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 32.33 Bn | 30.39 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 27.49 Bn | 23.43 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.14 Bn | 20.99 Bn | 648.10 Mn | 274.90 Mn |
| 6 | RedHill Biopharma | 20.53 Bn | 20.53 Bn | - | - |
| 7 | Viatris | 20.29 Bn | 18.49 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.93 Bn | 16.62 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.63 Bn | 12.21 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Alvotech | 927.36 Mn | 927.36 Mn | 5.09 Mn | 123,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 123,000.00 |
| Dec 31, 2025 | 299.90 Mn |
| Sep 30, 2025 | -307.87 Mn |
| Jun 30, 2025 | 57.96 Mn |
| Mar 31, 2025 | 126.18 Mn |
| Dec 31, 2024 | -223.39 Mn |
| Sep 30, 2024 | -303.58 Mn |
| Jun 30, 2024 | 148.46 Mn |
| Mar 31, 2024 | -213,111.00 |
| Dec 31, 2023 | -651.14 Mn |
| Aug 31, 2023 | -86.85 Mn |
| Jun 30, 2023 | 138.48 Mn |
| Mar 31, 2023 | -246,152.00 |
| Dec 31, 2022 | -540.69 Mn |
| Aug 31, 2022 | -184.47 Mn |
| Jun 30, 2022 | 264.69 Mn |
| Mar 31, 2022 | -58.90 Mn |
| Dec 31, 2021 | 206.23 Mn |
| Sep 30, 2021 | -33.79 Mn |